Welcome to our dedicated page for Altamira Therapeutics news (Ticker: CYTO), a resource for investors and traders seeking the latest updates and insights on Altamira Therapeutics stock.
Altamira Therapeutics Ltd. (historically Nasdaq: CYTO) generates news primarily around its RNA delivery platforms, legacy therapeutic assets, and capital markets activity. Company announcements describe ongoing development of its peptide-based nanoparticle technologies OligoPhore and SemaPhore for efficient RNA delivery to extrahepatic tissues, along with preclinical progress in its flagship siRNA programs AM-401 for KRAS-driven cancer and AM-411 for rheumatoid arthritis.
News items frequently cover business updates and financial results, where Altamira outlines its strategic repositioning around RNA delivery, reports on research milestones, and discusses collaborations with biotech and pharma partners. Press releases have highlighted independent preclinical publications using its SemaPhore platform in oncology and inflammatory disease models, as well as internal advances in nanoparticle formulation and process development.
Altamira-related news also includes developments from its associated company Altamira Medica AG and the commercial-stage nasal spray Bentrio. Announcements have detailed license and distribution agreements for Bentrio in regions such as East and South East Asia and Scandinavia, expansion of partner territories, and clinical data supporting its use in allergic rhinitis and protection against airborne particles. Additional releases have addressed topics like Bentrio’s suitability for athletes based on analytical testing for substances on the World Anti-Doping Agency list.
Capital markets and listing updates form another important category of news. The company has issued releases on public offerings of common shares and warrants, use of proceeds for working capital and research, and its transition from the Nasdaq Capital Market to the OTCQB marketplace following a Nasdaq delisting decision related to the minimum bid price rule. Investors following CYTO can use this news stream to monitor scientific progress, partnering activity, commercialization steps for Bentrio, and changes in trading venue or financing transactions.
Altamira Therapeutics Ltd. (NASDAQ:CYTO) announced an expansion of its marketing and distribution agreement for Bentrio™ with Wellesta Holding Pte Ltd, adding the Philippines and Morocco to its existing markets. This agreement now covers a total of eight countries, aiming to leverage Wellesta's experience in these new regions, which represent significant population bases: approximately 110 million in the Philippines and 37 million in Morocco. Bentrio™ is a drug-free nasal spray designed to protect against airborne viruses and allergens.
Altamira Therapeutics Ltd. (NASDAQ:CYTO) announced a marketing agreement with Avernus Pharma Ltd. to distribute its nasal spray, Bentrio, in several Gulf countries. The product aims to protect against airborne viruses and allergens. Bentrio demonstrated a more than 99% reduction in SARS-CoV-2 viral load in laboratory tests and alleviated allergic rhinitis symptoms. Sales in the region are projected to begin in 2022 following regulatory approvals. This collaboration leverages Avernus' strong distribution network in the Middle East.
Altamira Therapeutics Ltd. (NASDAQ:CYTO) has announced the formation of a new business unit, OTC Consumer Health, aimed at enhancing its global roll-out of Bentrio™, a nasal spray that protects against airborne viruses and allergens. This unit will be led by Jean Lachance, an experienced marketing strategist with over 20 years in the OTC consumer health sector. His leadership is expected to drive growth for Bentrio in 2022 and beyond.
Altamira Therapeutics Ltd. (NASDAQ:CYTO) announced the approval of its nasal spray, Bentrio™, by the Medical Device Authority of Malaysia, allowing for commercialization in the country. This follows previous clearance in Singapore, with Wellesta Holdings Pte Ltd set to manage distribution across several Asian markets, including India and Indonesia. CEO Thomas Meyer expressed optimism about Bentrio contributing significantly to revenue in 2022 as they aim to protect consumers from airborne allergens and viruses.
Altamira Therapeutics Ltd. (NASDAQ:CYTO) has appointed Covadonga Pañeda, Ph.D., as Chief Development Officer, enhancing its leadership team focused on RNA therapeutics. Effective April 2022, Dr. Pañeda will supervise the development of the company’s OligoPhore and SemaPhore platforms for RNA delivery. Additionally, the company received a Small Business Technology Transfer (STTR) grant from the NIH to advance its siRNA delivery technology aimed at treating inflammatory disorders, targeting diseases beyond the liver.
Altamira Therapeutics Ltd. (NASDAQ:CYTO) announced that its Chairman and CEO, Thomas Meyer, will present at the H.C. Wainwright BioConnect Conference from January 10-13, 2022. The presentation will be available on-demand starting January 10 at 7:00 AM ET on the conference portal and the company's website under 'Events and Presentations' in the 'Investors & Media' section. Altamira focuses on RNA therapeutics, viral infection protection, and inner ear therapeutics, with several products in various stages of development, including AM-125 for vertigo and Keyzilen for tinnitus.
Altamira Therapeutics Ltd. (NASDAQ:CYTO) has announced significant advancements regarding Bentrio™, its nasal spray designed for protection against airborne viruses and allergens. The product is now available on Amazon in Germany and has secured distribution agreements covering six Asian countries. Clinical trials for Bentrio™ against COVID-19 and allergy-related conditions are in progress, with results expected in the first half of 2022. The company is also preparing to evaluate Bentrio™ against the Omicron variant.
Altamira Therapeutics Ltd. (NASDAQ:CYTO) has randomized the first group of patients in a clinical trial for Bentrio (AM-301), aimed at treating house dust mite allergic rhinitis. The trial will enroll 36 patients, assessing the efficacy of the drug-free nasal spray against perennial allergic rhinitis under controlled exposure. Top-line results are expected by spring. Bentrio is currently marketed in various countries and aims to provide relief from airborne allergens and viruses, making it a viable option for allergy sufferers worldwide.
Altamira Therapeutics Ltd. (NASDAQ:CYTO) has initiated the NASAR trial, randomizing its first patient to evaluate the Bentrio™ (AM-301) nasal spray for seasonal allergic rhinitis (SAR). The trial will involve 100 patients and compare Bentrio™'s efficacy and safety against a saline spray over two weeks. Conducted during the pollen season in Australia, it aims to assess Bentrio™'s protective effects against airborne allergens. This follows positive results from earlier studies indicating rapid and durable effects against allergic rhinitis.
Altamira Therapeutics (NASDAQ:CYTO) announced promising results from two studies on RNA delivery platforms for treating abdominal aortic aneurysm (AAA) at the AHA Scientific Sessions 2021. The studies demonstrated that siRNA polyplexes targeting NF-kB significantly reduced AAA progression and aorta rupture, protecting 100% of mice in trials. Additionally, mRNA polyplexes targeting SOD-2 helped mitigate aneurysm expansion. These findings emphasize the potential of Altamira's delivery technologies for addressing AAA, a condition with high mortality rates if untreated.